Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Ainos Inc (AIMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: AIMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -77.85% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.48M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.22 | 52 Weeks Range 0.40 - 2.60 | Updated Date 06/29/2025 |
52 Weeks Range 0.40 - 2.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2978.02% |
Management Effectiveness
Return on Assets (TTM) -30.93% | Return on Equity (TTM) -82.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 61772226 | Price to Sales(TTM) 98.68 |
Enterprise Value 61772226 | Price to Sales(TTM) 98.68 | ||
Enterprise Value to Revenue 581.62 | Enterprise Value to EBITDA -1.6 | Shares Outstanding 20960200 | Shares Floating 9206027 |
Shares Outstanding 20960200 | Shares Floating 9206027 | ||
Percent Insiders 65.58 | Percent Institutions 0.55 |
Upturn AI SWOT
Ainos Inc
Company Overview
History and Background
Ainos Inc., formerly known as Applied BioTech, Inc., focuses on developing medical technologies. Founded with the goal of improving healthcare outcomes, the company has transitioned to a focus on antiviral and immuno-modulatory therapies. Key milestones include clinical trials for its VELDONA drug and expansion into new markets.
Core Business Areas
- Anti-Viral Therapy: Ainos develops and seeks to commercialize antiviral therapeutics, specifically targeting infectious diseases. This segment involves research, development, and clinical trials of potential drug candidates.
- Immuno-Modulatory Therapy: The company also focuses on immuno-modulatory therapies designed to enhance the body's immune response. This involves developing products that can help regulate the immune system.
Leadership and Structure
The leadership team consists of executives with experience in pharmaceutical development and regulatory affairs. The company operates with a typical corporate structure, including a board of directors, executive management, and various departments for research, development, and marketing.
Top Products and Market Share
Key Offerings
- VELDONA: VELDONA is an interferon alpha oral tablet being developed as an immuno-modulatory therapy for treating viral infections and potentially boosting the immune system. Clinical trials are underway. Competitors include other interferon-based therapies and broader antiviral drugs from companies like Gilead Sciences (GILD) and Roche (RHHBY).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and heavily regulated. There is a constant demand for new and improved therapies, especially in the anti-viral and immuno-oncology sectors. This landscape includes companies that develop a broad spectrum of offerings and those that have niche focus and expertise.
Positioning
Ainos is a small biotechnology company attempting to enter and compete in a market dominated by larger pharmaceutical companies. Its competitive advantage hinges on clinical trial success and potentially innovative products in niche markets.
Total Addressable Market (TAM)
The global antiviral drug market is estimated at hundreds of billions. Ainos' market position is extremely small at this stage with almost no commercialized products and future revenue prospects dependent on success of current projects.
Upturn SWOT Analysis
Strengths
- Focused on specific therapeutic areas (antiviral, immuno-modulatory)
- Potential for innovative therapies
- Intellectual property protection
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Small market presence compared to established competitors
- Lack of commercially available products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new markets
- Acquisition of complementary technologies
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturns affecting R&D funding
Competitors and Market Share
Key Competitors
- GILD
- RHHBY
- MRK
- PFE
- ABBV
Competitive Landscape
Ainos faces significant competition from larger pharmaceutical companies with established product portfolios, extensive resources, and global distribution networks.
Growth Trajectory and Initiatives
Historical Growth: Ainos' growth is currently reliant on pipeline product advancement.
Future Projections: Future growth prospects are contingent upon clinical trial outcomes and regulatory approvals, making projections speculative.
Recent Initiatives: Recent initiatives are centered on clinical trials for VELDONA and strategic partnerships.
Summary
Ainos Inc is a small biotech company with significant risk due to its reliance on clinical trials and limited resources. Its success depends on favorable clinical trial outcomes and regulatory approvals. It needs to navigate the competitive landscape dominated by much larger players. Any acquisitions by Ainos could improve valuation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share estimates are approximations and may vary. All financial data should be independently verified. Investing in AIMD (Ainos Inc) is extremely speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ainos Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-11-04 | CEO, President & Chairman of the Board Mr. Chun-Hsien Tsai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 44 | Website https://www.ainos.com |
Full time employees 44 | Website https://www.ainos.com | ||
Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.